Fig. 5: Bleeding-free anticoagulation in an artificial lung model in rabbits.
Rabbits were connected veno-venous to an artificial lung system for four hours. FXII900 was injected as a bolus (2 mg kg−1) before the start of the extracorporeal circulation and as a constant infusion (0.075 mg kg−1 min−1) over the full time course of the experiment (n = 4; data shown in blue). Rabbits in the control group were untreated (n = 3, data shown in red). Rabbits in the heparin group (n = 2) were initially infused with one IU per min heparin and the drip rate was adjusted to maintain ACT values between 220 and 300 s. Values indicated for the time point 0 refer to measurements made before connecting the artificial lung. Mean ± SD is indicated for the four rabbits in the FXII900-treated group and the three rabbits in the control group. Mean values are indicated for the two rabbits in the heparin group. Data from individual rabbits is shown in Supplementary Fig. 12. a aPTT. Coagulation times of 240 s indicate that plasma did not coagulate at this time. b ACT. Clotting times of 1500 s indicate that blood did not coagulate at this time. c Resistance calculated based on pressure at the inlet and outlet of the device and the flow rate. d Bleeding time measured by incision-provoked injuries at the ears. e Platelet count. f Volume of blood clots indicated in % of volume of the artificial lungs.
